Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in Its Transition Toward Commercial Revenue Generation

What was reported

HOUSTON – October 1, 2026 – Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has signed a definitive international distribution agreement (the “Agreement”) with Inovanexa Medical Technologies S.A. (the “Distributor”), appointing the Distributor as Nexalin’s exclusive distributor for the importation, distribution, commercialization, promotion and sale of the Company’s Nexalin Sync™ non-invasive neurostimulation device — which has been approved by Brazil’s National Health Surveillance Agency (ANVISA) for the treatment of anxiety, depression and insomnia — across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, a combined territory of more than 300 million people.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 1, 2026 · Open the source ↗

What the evidence supports

Nexalin Technology told the SEC (Form 8-K, Item 1.01) that it signed an agreement it considers material. The filing gives Sep 28, 2026 as the date of the earliest event reported. The company also furnished a press release, which is its own account rather than a regulatory statement.

What remains unknown

Whether the agreement produces revenue, when, or on what terms beyond those disclosed. Figures and claims are the company's own description and have not been independently verified.

Source passages

Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.

Press release headlineNexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in Its Transition Toward Commercial Revenue GenerationU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 1, 2026 · Open the source ↗

Press release lead paragraphHOUSTON – October 1, 2026 – Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has signed a definitive international distribution agreement (the “Agreement”) with Inovanexa Medical Technologies S.A. (the “Distributor”), appointing the Distributor as Nexalin’s exclusive distributor for the importation, distribution, commercialization, promotion and sale of the Company’s Nexalin Sync™ non-invasive neurostimulation device — which has been approved by Brazil’s National Health Surveillance Agency (ANVISA) for the treatment of anxiety, depression and insomnia — across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, a combined territory of more than 300 million people.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Oct 1, 2026 · Open the source ↗

Revision history

1. Revision 1 · Oct 28, 2026, 20:54 UTC

   Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in Its Transition Toward Commercial Revenue Generation

Spotted an error? Tell us. Corrections are published, never silent: see all corrections.